Sugi Predict

Sugi Predict / Compounds / SCHEMBL919744

SCHEMBL919744

SCHEMBL919744

COC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 3/20 0.54
▸ NR1H3 Q13133 1/20 0.54
▸ MMP1 P03956 2/20 0.45
▸ MMP9 P14780 2/20 0.45
▸ MMP3 P08254 1/20 0.45
▸ MMP7 P09237 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ HSD17B10 Q99714 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ EPHX2 P34913 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ SETD7 Q8WTS6 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1849268 1.00 NR1H2 (0.54) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL282661 1.00 NR1H2 (0.54) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL282254 0.94 NR1H2 (0.50) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL28060561 0.93 NR1H2 (0.53) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL25312339 0.91 NR1H2 (0.47) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL26427027 0.91 NR1H2 (0.47) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL16931220 0.91 NR1H2 (0.47) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL14278266 0.91 NR1H2 (0.47) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL16931222 0.91 NR1H2 (0.47) NR1H2NR1H3MMP1MMP9MMP3
SCHEMBL22608782 0.90 NR1H2 (0.46) NR1H2NR1H3MMP1MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448389-B2 BRM targeting compounds and associated methods of use PRELUDE THERAPEUTICS INCORPORATED (US) 2025-10-21 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
EP-4570319-A2 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Prelude Therapeutics Incorporated (US) 2025-06-18 — — EP disclosed
EP-4161935-B1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INC (US) 2025-05-21 — — EP disclosed
EP-4522621-A1 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER Prelude Therapeutics Incorporated (US) 2025-03-19 — — EP disclosed
WO-2024182747-A2 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 — — WO disclosed
EP-4420732-A2 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG Pharmaceutical Co., Ltd. (KR) 2024-08-28 — — EP disclosed
WO-2024133560-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS DARK BLUE THERAPEUTICS LTD (GB) 2024-06-27 — — WO disclosed
EP-3233863-B1 FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS CMG PHARMACEUTICAL CO LTD (KR) 2024-04-10 — — EP disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 — — US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 — — US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 — — US disclosed
WO-2010011772-A2 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-01-28 — — WO disclosed
EP-2007787-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES Novartis AG (CH) 2008-12-31 — — EP disclosed
US-20080045530-A1 Organic Compounds and Their Uses BRANDL TRIXI 2008-02-21 — — US disclosed
WO-2007121124-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES NOVARTIS AG (CH) 2007-10-25 — — WO disclosed
WO-2007120595-A2 AMINES FOR THE TREATMENT OF HCV NOVARTIS AG (CH) 2007-10-25 — — WO disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 — — US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045530-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 NR1H2 531/4885NR1H3 459/4885MMP1 887/4885
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R NR1H2 296/4885NR1H3 474/4885MMP1 3977/4885
US-12448389-B2 BRM targeting compounds and associated methods of use ADRM1, BRDT, RBX1 NR1H2 2591/4885NR1H3 2496/4885MMP1 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.